Glaukos: Still Bullish, But Embedded Expectations Are Now High
Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sales, with high expectations for future growth, but a 27% margin of safety exists at current prices. GKOS's efficient asset base and strong cash conversion support sustainable growth, driven by iDose TR and iStent infinite uptake in domestic and international markets.
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
5 Medical Device Stocks That Survived the 2024 Market Volatility
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?
GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Glaukos Corp GKOS reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million.
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Lawrence Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Allen Gong - JPMorgan David Saxon - Needham Michael Sarcone - Jefferies Joanne Wuensch - Citigroup Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Welcome to Glaukos Corporation's Third Quarter 2024 Financial Results Conference Call.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.
Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
